Vol. 37 No. 2 (2020)

Click for printable Cover and Index

Published: 08-07-2020

  • Sarcoidosis Vasculitis and Diffuse Lung Disease: alive and still growing

    DOI: https://doi.org/10.36141/svdld.v37i2.10080
    Robert P. Baughman, Antonella Caminati, Claudia Ravaglia, Luca Richeldi, Paola Rottoli, Sara Tomassetti, Carlo Vancheri
    86

  • Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy

    DOI: https://doi.org/10.36141/svdld.v37i2.9599
    Huzaefah Syed, Christian Ascoli, Catharina Linssen, Christen Vagts, Thomas Iden, Aamer Syed, Jordana Kron, Kelly Polly, David Perkins, Patricia Finn, Richard Novak, Marjolein Drent, Robert Baughman, Nadera Sweiss
    87-98

  • The right upper lobe bronchus angle: A tool for differentiating fibrotic and non-fibrotic sarcoidosis

    DOI: https://doi.org/10.36141/svdld.v37i2.8965
    Mary Salvatore, Danielle Toussie, Nadiya Pavlishyn, David Yankelevitz, Timothy O'Connor, Claudia Henschke, Maria Padilla
    99-103

  • Sarcoidosis and increased risk of comorbidities and mortality in Sweden Sarcoidosis - Comorbidities and Mortality

    DOI: https://doi.org/10.36141/svdld.v37i2.9142
    Johanna Larsson, Pål Graff, Ing-Liss Bryngelsson, Per Vihlborg
    104-135

  • Treatment of Primary Sjögren’s Syndrome-Related Interstitial Lung Disease: a Retrospective Cohort Study

    DOI: https://doi.org/10.36141/svdld.v37i2.8461
    Barkha Amlani, Ghada Elsayed, Umang Barvalia, Jeffrey P Kanne, Keith C Meyer, Nathan Sandbo, Zhanhai Li, Sara S McCoy
    136-147

  • A real-world study of the tolerability and dosing of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis Pirfenidone dose and survival in IPF

    DOI: https://doi.org/10.36141/svdld.v37i2.8718
    Sahajal Dhooria, Ritesh Agarwal, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Valliappan Muthu, Mandeep Garg, Amanjit Bal, Ashutosh Nath Aggarwal, Digambar Behera
    148-157

  • Predictors of cough-specific and generic quality of life in sarcoidosis patients

    DOI: https://doi.org/10.36141/svdld.v37i2.9234
    Branislav S. Gvozdenovic, Violeta Mihailovic-Vucinic, Mira Vukovic, Mihailo Stjepanovic, Ivana Buha, Strahinja V. Mihailovic, Nikola B. Maric
    158-168

  • Obstructive sleep apnea in sarcoidosis and impact of CPAP treatment on fatigue

    DOI: https://doi.org/10.36141/svdld.v37i2.9169
    Pier-Valerio Mari, Giuliana Pasciuto, Matteo Siciliano, Jacopo Simonetti, Federico Ballacci, Francesco Macagno, Bruno Iovene, Filippo Martone, Giuseppe Maria Corbo, Luca Richeldi
    169-178

  • A unique case of ovarian manifestation of systemic vasculitis that mimics ovarian cancer.

    DOI: https://doi.org/10.36141/svdld.v37i2.8181
    Ada Bielejewska, Arkadiusz Bociek, Martyna Bociek, Andrzej Jaroszyński
    179-183

  • Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertensio

    DOI: https://doi.org/10.36141/svdld.v37i2.9150
    Eric Abston, Matthew Moll, Stephanie Hon, Praveen Govender, Jeffrey Berman, Harrison Farber
    184-191

  • The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study

    DOI: https://doi.org/10.36141/svdld.v37i2.9433
    Monique Wapenaar, Elisabeth Bendstrup, Maria Molina-Molina, Maarten K.N. Stessel, Jasmina Huremovic, Eric W. Bakker, Isabella Kardys, Joachim G.J.V. Aerts, Marlies S. Wijsenbeek
    192-202

  • Associations between interleukin 18 gene polymorphisms and susceptibility to vasculitis: A meta-analysis IL18 polymorphisms in vasculitis

    DOI: https://doi.org/10.36141/svdld.v37i2.9399
    Jae Hyun Jung, Han Saem Jeong, Sung Jae Choi, Gwan Gyu Song, Jong-Ho Kim, Tae Hyub Lee, Youngjin Han
    203-211

  • Role of alveolar collapse in idiopathic pleuroparenchymal fibroelastosis

    DOI: https://doi.org/10.36141/svdld.v37i2.9981
    Yoshiaki Kinoshita, Hiroshi Ishii, Hisako Kushima, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe
    212-217

  • Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study

    DOI: https://doi.org/10.36141/svdld.v37i2.8587
    James Eaden, Christopher M. Barber, Stephen Renshaw, Nazia Chaudhuri, Stephen Bianchi
    218-224

  • Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease

    DOI: https://doi.org/10.36141/svdld.v37i2.9098
    Ori Wand, Ben Fox, Osnat Shtraichman, Osnat Moreh-Rahav, Moti Kramer
    225-230

  • Rapidly non-IPF progressive fibrosing interstitial lung disease: a phenotype with an IPF-like behavior

    DOI: https://doi.org/10.36141/svdld.v37i2.9276
    Ngu Khine, Dalia Mudawi, Pilar Rivera-Ortega, Colm Leonard, Nazia Chaudhuri, George A. Margaritopoulos
    231-233

  • Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy

    DOI: https://doi.org/10.36141/svdld.v37i2.9343
    Eric Abston, Stephanie Hon, Romy Lawrence, Jeffrey Berman, Praveen Govender, Harrison W. Farber
    234-238

  • Pulmonary arterial hypertension secondary to Takayasu’s Arteritis: management using a combined medical and interventional approach

    DOI: https://doi.org/10.36141/svdld.v37i2.8987
    Matthew Nitzberg, Raj Parikh, Praveen Govender, Harrison W Farber
    239-241

  • Subcutaneous sarcoidosis: a report of 13 cases and its association with extracutaneous sarcoidosis

    DOI: https://doi.org/10.36141/svdld.v37i2.9199
    Toshiyuki Yamamoto
    242-245